Regulatory Intelligence | August 2026
EU AI Act Omnibus enters into force, WET exemptions widen clinical-evidence relief for established implantables, MDCG restricts UDI-DI assignment to manufacturers, and MHRA draws the regulatory line for ambient voice technology.
Prepared by SciMed Consultancy Ltd for regulatory, legal, quality, and market-access teams operating under EU MDR, IVDR, UK MDR, and related global frameworks.
THIS MONTH IN BRIEF
EU AI Act Omnibus enters into force: Regulation (EU) 2026/1744 published on the 24th of July, in force from the 27th of July
Confirms 2nd of December 2027 deadline for standalone high-risk AI, 2nd of August 2028 for MDR/IVDR-embedded systems
WET Delegated Regulations (EU) 2026/1359 and 2026/1451 enter into force, widening exemptions for well-established technologies
Expanded clinical-investigation relief (Article 61) and technical-documentation sampling (Article 52) for defined implantable and Class IIb devices
MDCG 2026-5: Only manufacturers may assign UDI-DIs
MHRA publishes Ambient Voice Technology guidance, setting the line between AI scribes and medical devices
swissdamed mandatory registration begins for the Swiss market
TGA UDI labelling becomes mandatory for Class IIb and Class III devices in Australia
INTRODUCTION
July's regulatory calendar was predominantly dominated by scheduled items we knew were coming, rather than by surprises. The AI Act Omnibus cleared its final procedural hurdle, two long-flagged national registration deadlines (Switzerland and Australia) came into effect, and the Commission's expanded well-established technology exemptions took hold. The one genuinely new item, MDCG's position paper on UDI assignment, closes a loophole that private-label arrangements had been quietly relying on for years.
The AI Act Omnibus is now Regulation (EU) 2026/1744, in force since the 27th of July. It confirms rather than changes the timeline flagged last month: standalone high-risk AI systems have until the 2nd of December 2027, and AI embedded in MDR/IVDR-regulated products has until the 2nd of August 2028. The shorter runway sits with transparency obligations, most of Article 50 (including AI-interaction disclosure) still applies from the 2nd of August this year, and systems already on the market before that date have only until the 2nd of December 2026 to add synthetic-content labelling.
Elsewhere the pattern was operational rather than legislative. swissdamed and the Australian UDI mandate both went live on the 1stof July, converting deadlines that have sat in this briefing's table for months into active compliance obligations. The WET exemptions did the same in reverse, quietly removing a clinical-investigation requirement for a defined list of long-established implantable devices the moment they entered into force on the 19th of July.
RECENT DEVELOPMENTS | EU
EU AI Act Omnibus Enters Into Force: MedTech Timeline Confirmed as Regulation (EU) 2026/1744
The Digital Omnibus on AI was published in the Official Journal on the 24th of July 2026 and entered into force on the 27th of July, three days later. It is the first formal amendment to the AI Act since the legislation was adopted in June 2024, and settles the compliance timeline MedTech manufacturers have been working against since the original 2nd of August 2026 deadline was set.
The headline change is the postponement flagged last month: standalone high-risk AI systems under Annex III now have until the 2nd of December 2027, and AI systems embedded in products regulated under MDR, IVDR and other EU product safety legislation have until the 2nd of August 2028, rather than 2027. A narrower point is easy to miss though, transparency obligations under Article 50, including the duty to disclose that a user is interacting with an AI system, and the labelling of synthetic audio, image or video content, still apply from the 2nd of August 2026. Systems already on the market before that date have a grace period until the 2nd of December 2026 to add machine-readable content labelling; but anything placed on the market after the 2nd of August 2026 onwards must comply immediately.
Manufacturers of AI-enabled devices should treat the extended deadline as planning room rather than a reason to slow down. The underlying obligations, risk management documentation, technical file mapping against MDR/IVDR requirements, and QMS data governance, still take as long to build as they did last month.
»You can read the Digital Omnibus here.
WET Delegated Regulations Enter Into Force: Wider Relief for Established Implantables
We flagged two delegated regulations in last month's briefing, Commission Delegated Regulation (EU) 2026/1451 and (EU) 2026/1359 and both entered into force on the 19th of July 2026, twenty days after their original publication in the Official Journal at the end of June. Both expand the list of well-established technology (WET) devices recognised under the MDR.
Regulation 2026/1451 amends Article 61(6)(b), adding a wider range of implantable and Class III devices, including cannulas, catheters, feeding tubes, bone wax, bone fillers, bone substitutes, dental implants and orthodontic devices, to the list exempt from the obligation to perform a clinical investigation. Regulation 2026/1359 amends Article 52(4), extending the list of Class IIb implantable devices for which notified bodies are not required to assess technical documentation on a per-device basis. The two exemptions are legally distinct: a device can qualify for one, both, or neither.
Neither regulation removes the underlying requirement for a clinical evaluation based on sufficient clinical data. Manufacturers with WET-eligible devices in the portfolio should confirm which list applies to which product, and make sure the rationale for relying on the exemption is documented and defensible, not simply assumed.
»You can read Delegated Regulation 2026/1451 here (Article 61) and 2026/1359 here (Article 52).
MDCG 2026-5: Only Manufacturers May Assign UDI-DIs
Published on the 22nd of July 2026, MDCG 2026-5 closes a practice some distributors had treated as compliant: assigning their own UDI-DI to a device sold under their own brand name, while the manufacturer's details remained on the label. MDCG's position is unambiguous. Only the manufacturer, as identified on the label and in the device documentation, may assign UDI-DIs and register the device in EUDAMED.
The position paper does allow a single device to carry two different UDI-DIs when marketed under two different trade names, but both codes must be assigned by the manufacturer and linked back to the manufacturer with the relevant EU UDI issuing entity. Third parties, including distributors, may still interact with the issuing entity on the manufacturer's behalf; what they cannot do is hold their own manufacturer-equivalent UDI-DI registration.
Manufacturers operating private-label or multi-brand distribution arrangements should review how UDI-DIs have been assigned across their distributor network. Where a distributor has been assigning its own codes, the arrangement needs correcting and the EUDAMED registration reconciling before it attracts regulator attention.
»You can read the MDCG 2026-5 Position Paper here.
RECENT DEVELOPMENTS | UK
MHRA Publishes Ambient Voice Technology Guidance: Setting the Line Between AI Scribes and Medical Devices
On the 29th of July 2026, the MHRA published guidance, developed with NHS England, setting out how existing medical device law applies to ambient voice technology (AVT), the AI scribes and transcription tools now widely piloted across NHS trusts.
The dividing line is intended use. AVT products limited to transcription, summarising clinical conversations, drafting letters, or suggesting clinical codes for a clinician to review sit outside the medical device definition under the current framework. Products that support diagnosis, treatment or prevention, or that take automated action such as placing orders without clinician review, do qualify as medical devices and must meet the relevant safety and performance requirements.
For manufacturers and NHS organisations already deploying AVT tools, the guidance is worth checking against actual product functionality rather than marketing description; a tool marketed as a scribe that quietly nudges toward automated coding or ordering decisions may sit on the wrong side of the line the MHRA has just drawn.
»You can read the MHRA's AVT guidance here.
RECENT DEVELOPMENTS | Switzerland
swissdamed: Mandatory Registration Begins
From the 1st of July 2026, manufacturers and their authorised representatives must register medical devices, IVDs, systems and procedure packs in swissdamed, Switzerland's national device database, replacing the previous notification-based system. A transition period runs until the 31st of December this year for most products already on the Swiss market.
One category has no transition period though - Devices that must be reported to Swissmedic because of a serious incident, a field safety corrective action, or an identified trend require registration in swissdamed immediately, from the 1st of July, with no grace window. Registration fees apply per UDI-DI: CHF 200 for the first, CHF 20 for each additional, capped at CHF 10,000 per calendar year.
Manufacturers with Swiss market presence should confirm registration status now rather than waiting for the December deadline, particularly for any device with an open incident or FSCA history.
»You can read the Swissmedic's swissdamed announcement here.
Recent Developments | Australia
TGA UDI Mandate: Takes Effect for Higher-Risk Devices
From the 1st of July 2026, UDI labelling and AusUDID data submission became mandatory in Australia for Class IIb and Class III medical devices, the first phase of the TGA's staged UDI rollout; with lower-risk classes to follow over the coming years. The same date brought a routine annual increase to TGA fees and charges for FY2026-27, with annual charges up by around 6% and assessment fees up by around 5%.
Sponsors and manufacturers placing Class IIb or Class III devices on the Australian market should confirm UDI labelling and AusUDID registration are complete for any device supplied from the 1st of July onwards; a device already on the market without a compliant UDI risks supply disruption rather than a simple paperwork gap.
»You can read the TGA's UDI guidance here.
UPCOMING DEADLINES
The following confirmed deadlines fall will be upon us soon. Manufacturers, importers, and authorised representatives should verify their compliance status against each.
2nd August 2026 | EU AI Act
Articles 5 (prohibited AI practices) and 4 (AI literacy) obligations remain in effect. Synthetic-content systems placed on the market from this date must carry machine-readable labelling immediately; systems already on the market have until the 2nd of December 2026.
27th Novemebr 2026 | EU
Legacy devices must be registered in the UDI/Device module of EUDAMED
2nd December 2026 | EU AI Act
Deadline for AI systems already on the market before the 2nd of August 2026 to complete machine-readable labelling of synthetic audio, image, video or text content under Article 50.
31st December 2026 | Swissmedic
Transition period for swissdamed registration ends for devices not subject to incident, FSCA or trend reporting.
2nd August 2027 | EU AI Act
Forward Planning
National competent authorities must have established at least one AI regulatory sandbox.
2nd December 2027 | EU AI Act
Forward Planning
Full high-risk obligations apply to standalone Annex III AI systems.
2nd August 2028 | EU AI Act
Forward Planning
Full high-risk obligations apply to AI systems embedded in MDR/IVDR-regulated products.
Need help interpreting how these changes affect your organisation?
Regulatory changes rarely affect products in isolation. Classification strategy, evidence planning, market access, software change control, supply continuity, and lifecycle obligations increasingly overlap across jurisdictions.
If your team is assessing the operational or commercial implications of any of the developments above, we can help pressure-test the impact against your specific products, portfolio, or regulatory strategy.
